Progress in Neurotherapeutics and Neuropsychopharmacology 2008

Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurological and psychiatric illnesses, and non-drug treatments. Each article is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an Editor-in-Chief and Editorial Board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of recent trials in all aspects of the management of neurological and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists. Articles also available at http://www.cambridge.org/jid_PNN
Editor-in-Chief
Jeffrey L. Cummings, MD
Department of Neurology and Psychiatry and Biobehavioral Sciences,
David Geffen School of Medicine at UCLA,
Los Angeles, CA, USA

Editorial Board
Peter Goadsby, MD, PhD
Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK

Karl Kieburtz, MD, FAAN
Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA

Joseph Masdeu, MD, PhD, FAAN
Department of Neurology, University of Navarre Medical School Pamplona, Spain

Gary Tollefson, MD, PhD
Orexigen Therapeutics, Inc. and Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA
Progress in Neurotherapeutics and Neuropsychopharmacology
2008

VOL. 3(1) 2008

Editor-in-Chief
Jeffrey L. Cummings, MD
The Augustus S. Rose Professor of Neurology
Professor of Psychiatry and Biobehavioral Sciences
Director, Mary S. Easton Center for Alzheimer’s Disease Research
Director, Deane F. Johnson Center for Neurotherapeutics
David Geffen School of Medicine at UCLA
Dedicated

Kate (Zhong) Cummings

There is only one happiness in life – to love and be loved.
– George Sand
Contents

ix Contributors

1 Progress in Neurotherapeutics and Neuropsychopharmacology 2008
   Jeffrey L. Cummings

13 Triflusul versus Aspirin for the Prevention of Stroke
   Antonio Culebras, Javier Borja and Julián García-Rafanell

35 The Argatroban and tPA Stroke Study
   Andrew D. Barreto and James C. Grotta

49 Use of Selegiline as Monotherapy and in Combination with Levodopa in the Management of Parkinson’s Disease: Perspectives from the MONOCOMB Study
   Sven E. Pålhagen and Esa Heinonen

73 Ropinirole 24-h Prolonged Release in Advanced Parkinson Disease: Review of a Randomized, Double-Blind, Placebo-Controlled Study (EASE PD - Adjunct Study)
   Kelly E. Lyons and Rajesh Pahwa

85 Insulin Resistance Alzheimer’s Disease: Pathophysiology and Treatment
   G. Stennis Watson and Suzanne Craft

111 Targeting Amyloid with Tramiprosate in Patients with Mild-to-Moderate Alzheimer Disease
   P.S. Aisen, R. Briand, D. Saumier, J. Laurin, A. Duong and D. Garceau

127 Intranasal Zolmitriptan Is Effective and Well Tolerated in Acute Cluster Headache: A Randomized Placebo-Controlled Double-Blind Crossover Study
   E. Cittadini and P.J. Goodby

137 Optimal Dosing of Immunomodulating Drugs: A Dose-Comparison Study of GA in RRMS
   Daniel Wynn, Catherine Meyer, Neil Allen and Dennis O’Brien
Contents

153  Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson’s Disease
    George J. Brewer, Fred Askari, Matthew T. Lorincz, Martha Carlson, Michael Schilsky, Karen J. Kluin, Peter Hedera, Paolo Moretti, John K. Fink, Roberta Tankanow, Robert B. Dick and Julia Sitterly

167  Randomized Clinical Trials of Pregabalin for Neuropathic Pain: Methods, Results, and Implications
    Robert H. Dworkin, Rajbala Thakur, Teresa Griesing, Uma Sharma and James P. Young

189  Effect of Methylphenidate in Patients with Acute Traumatic Brain Injury; a Randomized Clinical Trial
    Hossein A. Khalili and Kamyar Keramatian

199  Improvement in Speeded Cognitive Processing After Anti-epileptic Drug Withdrawal – A Controlled Study in Mono-therapy Patients
    Erik Hessen, Morten I. Lossius, Ivar Reinvang and Leif Gjerstad

211  A Randomized-Controlled Trial of Bilateral rTMS for Treatment-Resistant Depression
    Paul B. Fitzgerald

227  Serotonin Related Genes Affect Antidepressant Treatment in Obsessive—Compulsive Disorder
    F. Van Nieuwerburgh, D. Deforce and D.A.J.P. Denys

241  Night Eating Syndrome and Results from the First Placebo-Controlled Trial of Treatment, with the SSRI Medication, Sertraline: Implications for Clinical Practice
    John P. O’Reardon, Karen E. Groff, Albert J. Stunkard and Kelly C. Allison

259  Modafinil: A Candidate for Pharmacotherapy of Negative Symptoms in Schizophrenia
    John H. Peloian and Joseph M. Pierre

275  New Approaches to Treatment of Schizophrenia by Enhancing N-methyl-D-aspartate Neurotransmission
    Guochuan Emil Tsai

291  Subject Index

299  Author Index
Contributors

P.S. Aisen
Department of Neurology
Georgetown University Medical Center
Washington DC, USA

Neil Allen
Consultants in Neurology
Northbrook, IL, USA

Kelly C. Allison
Weight & Eating Disorders Program
Department of Psychiatry
University of Pennsylvania
Philadelphia, PA, USA

Fred Askari
Department of Internal Medicine
University of Michigan
Ann Arbor, MI, USA

Andrew D. Barreto
Department of Neurology
Stroke Division
The University of Houston-Texas Health Science Center
Houston, TX, USA

Javier Borja
Drug Safety Manager
J. Uriach y Compañía, S.A.
Poligon Industrial Riera de Caldes
Avinguda Camí Reial
Palau-solità i Plegamans
Barcelona, Spain

George J. Brewer
Department of Human Genetics
Department of Internal Medicine
University of Michigan
Ann Arbor, MI, USA

R. Briand
Neurochem Inc.
Laval, Quebec, Canada

Martha Carlson
Department of Pediatrics-Neurology
University of Michigan
Ann Arbor, MI, USA

E. Cittadini
Headache Group
Institute of Neurology
The National Hospital for Neurology and Neurosurgery
Queen Square, London, UK

Suzanne Craft
Geriatric Research, Education, and Clinical Center (GRECC)
Veterans Affairs Puget Sound Health Care System

Antonio Culebras
Department of Neurology
Upstate Medical University
Syracuse, NY, USA

Jefrey L. Cummings
Departments of Neurology and Psychology and Behavioral Sciences
David Geffen School of Medicine at UCLA
Los Angeles, CA, USA
Contributors

D. Deforce
Laboratory of Pharmaceutical Biotechnology
Ghent University
Ghent, Belgium

D.A.J.P. Denys
AMC
University of Amsterdam
Amsterdam, The Netherlands

Robert B. Dick
Department of Human Genetics
University of Michigan
Ann Arbor, MI, USA

A. Duong
Neurochem Inc.
Laval, Quebec, Canada

Robert H. Dworkin
Departments of Anesthesiology and Neurology
University of Rochester School of Medicine and Dentistry
Rochester, NY, USA

John K. Fink
Department of Neurology
University of Michigan
Ann Arbor, MI, USA

Paul B. Fitzgerald
Alfred Psychiatry Research Centre
The Alfred and Monash University
School of Psychiatry, Psychology and Psychological Medicine
Melbourne, Victoria, Australia

D. Garceau
Neurochem Inc.
Laval, Quebec, Canada

Julián García-Rafanell
Director of Medical Affairs
J. Uriach y Compañía, S.A.
Poligon Industrial Riera de Caldes
Avinguda Camí Reial
Palau-solità i Plegamans
Barcelona, Spain

Leif Gjerstad
Department of Neurology
Rikshospitalet
University of Oslo
Norway

P.J. Goadsby
Headache Group
Institute of Neurology
The National Hospital for Neurology and Neurosurgery
Queen Square, London, UK

Department of Neurology
University of California
San Francisco, CA, USA

Teresa Griesing
Pfizer, Inc.
New York, NY, USA

Karen E. Groff
Weight & Eating Disorders Program
Department of Psychiatry
University of Pennsylvania
Philadelphia, PA, USA

James C. Grotta
Department of Neurology
Stroke Division
The University of Houston-Texas
Houston, TX, USA

Peter Hedera
Department of Neurology
Vanderbilt University
Nashville, TN, USA

Esa Heinonen
University of Helsinki
Institute of Biotechnology
Helsinki, Finland

Erik Hessen
Helse Øst Health Services and
Department of Neurology
Akershus University Hospital
Norway
### Contributors

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>City, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kamyar Keramatian</td>
<td>Neuroscience Program</td>
<td>Vancouver, Canada</td>
</tr>
<tr>
<td>Hossein A. Khalili</td>
<td>Department of Neurosurgery</td>
<td>Shiraz, Iran</td>
</tr>
<tr>
<td>Karen J. Klun</td>
<td>Department of Neurology</td>
<td>Ann Arbor, MI, USA</td>
</tr>
<tr>
<td>J. Laurin</td>
<td>Neurochem Inc.</td>
<td>Laval, Quebec, Canada</td>
</tr>
<tr>
<td>Matthew T. Lorincz</td>
<td>Department of Neurology</td>
<td>Ann Arbor, MI, USA</td>
</tr>
<tr>
<td>Morten I. Lossius</td>
<td>Helse Øst Health Services and Akershus University Hospital</td>
<td>Norway and National Center for Epilepsy Rikshospitalet University of Oslo Norway</td>
</tr>
<tr>
<td>Kelly E. Lyons</td>
<td>Department of Neurology</td>
<td>Kansas City, USA</td>
</tr>
<tr>
<td>Catherine Meyer</td>
<td>Consultants in Neurology</td>
<td>Northbrook, IL, USA</td>
</tr>
<tr>
<td>Paolo Moretti</td>
<td>Departments of Neurology and Molecular and Human Genetics</td>
<td>Houston, TX, USA</td>
</tr>
<tr>
<td>Dennis O’Brien</td>
<td>Billings Clinic</td>
<td>Billings, MT, USA</td>
</tr>
<tr>
<td>John P. O’Reardon</td>
<td>Weight &amp; Eating Disorders Program</td>
<td>Philadelphia, PA, USA</td>
</tr>
<tr>
<td>Rajesh Pahwa</td>
<td>Department of Neurology</td>
<td>Kansas City, USA</td>
</tr>
<tr>
<td>Sven E. Pålhagen</td>
<td>Department of Neurology</td>
<td>Huddinge, Stockholm, Sweden</td>
</tr>
<tr>
<td>John H. Pelcian</td>
<td>Department of Psychiatry</td>
<td>VA Greater Los Angeles Healthcare System</td>
</tr>
<tr>
<td>Joseph M. Pierre</td>
<td>Department of Psychiatry</td>
<td>VA Greater Los Angeles Healthcare System</td>
</tr>
<tr>
<td>Ivar Reinvang</td>
<td>Department of Psychology</td>
<td>University of Oslo  Norway</td>
</tr>
<tr>
<td>D. Saumier</td>
<td>Neurochem Inc.</td>
<td>Laval, Quebec, Canada</td>
</tr>
<tr>
<td>Michael Schilsky</td>
<td>Department of Internal Medicine</td>
<td>Cornell University</td>
</tr>
<tr>
<td>New York, NY, USA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Contributors

Uma Sharma
Pfizer, Inc.
Ann Arbor, MI, USA

Julia Sitterly
Department of Human Genetics
University of Michigan
Ann Arbor, MI, USA

Albert J. Stunkard
Weight & Eating Disorders Program
Department of Psychiatry
University of Pennsylvania
Philadelphia, PA, USA

Roberta Tankanow
College of Pharmacy
University of Michigan
Ann Arbor, MI, USA

Rajbala Thakur
Department of Anesthesiology
University of Rochester School of Medicine and Dentistry
Rochester, NY, USA

Guochuan Emil Tsai
Department of Psychiatry
Harbor-UCLA Medical Center
Torrance, CA, USA

F. Van Nieuwerburgh
Laboratory of Pharmaceutical Biotechnology
Ghent University
Ghent, Belgium

G. Stennis Watson
Geriatric Research, Education, and Clinical Center (GRECC)
Veterans Affairs Puget Sound Health Care System and Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Seattle, WA, USA

Daniel Wynn
Consultants in Neurology
Northbrook, IL, USA

James P. Young
Pfizer, Inc.
Ann Arbor, MI, USA